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Abstract
Background: Endocannabinoids (ECs) and related N-acyl-ethanolamides (NAEs) play important roles in stress response
regulation, anxiety and traumatic memories. In view of the evidence that circulating EC levels are elevated under acute mild
stressful conditions in humans, we hypothesized that individuals with traumatic stress exposure and post-traumatic stress
disorder (PTSD), an anxiety disorder characterized by the inappropriate persistence and uncontrolled retrieval of traumatic
memories, show measurable alterations in plasma EC and NAE concentrations.
Methods: We determined plasma concentrations of the ECs anandamide (ANA) and 2-arachidonoylglycerol (2-AG) and the
NAEs palmitoylethanolamide (PEA), oleoylethanolamide (OEA), stearoylethanolamine (SEA), and N-oleoyldopamine (OLDA)
by HPLC-MS-MS in patients with PTSD (n = 10), trauma-exposed individuals without evidence of PTSD (n = 9) and in healthy
control subjects (n = 29). PTSD was diagnosed according to DSM-IV criteria by administering the Clinician Administered PTSD
Scale (CAPS), which also assesses traumatic events.
Results: Individuals with PTSD showed significantly higher plasma concentrations of ANA (0.4860.11 vs. 0.3660.14 ng/ml,
p = 0.01), 2-AG (8.9363.20 vs. 6.2662.10 ng/ml, p,0.01), OEA (5.9062.10 vs. 3.8861.85 ng/ml, p,0.01), SEA (2.7063.37 vs.
0.8360.47, ng/ml, p,0.05) and significantly lower plasma levels of OLDA (0.1260.05 vs. 0.4560.59 ng/ml, p,0.05) than
healthy controls. Moreover, PTSD patients had higher 2-AG plasma levels (8.9363.20 vs. 6.0161.32 ng/ml, p = 0.03) and also
higher plasma concentrations of PEA (4.0661.87 vs. 2.6361.34 ng/ml, p,0.05) than trauma-exposed individuals without
evidence of PTSD. CAPS scores in trauma-exposed individuals with and without PTSD (n = 19) correlated positively with PEA
(r= 0.55, p = 0.02) and negatively with OLDA plasma levels (r=20.68, p,0.01). CAPS subscores for intrusions (r=20.65,
p,0.01), avoidance (r=20.60, p,0.01) and hyperarousal (r=20.66, p,0.01) were all negatively related to OLDA plasma
concentrations.
Conclusions: PTSD appears to be associated with changes in plasma EC/NAE concentrations. This may have
pathophysiological and diagnostic consequences but will need to be reproduced in larger cohorts.
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Introduction
Endocannabinoids (ECs) and related N-acyl-ethanolamides
(NAEs) play an essential role in many physiological processes,
including energy metabolism, immune function and both central
and peripheral nervous system function [1]. They are also
implicated in a considerable number of pathophysiological
conditions such as cardiovascular disorders [2], systemic inflam-
mation and neuroinflammation [3,4], obesity and the metabolic
syndrome [5], cancer [6] and mental disorders such as depression
[7] and schizophrenia [8].The best investigated ECs are
anandamide (ANA) and 2-arachidonoylglycerol (2-AG) which
both bind to CB1 and CB2 receptors. However, there are a
number of other biologically highly active molecules which also
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have been linked to the EC system and show stress or memory-
modulating capabilities. These compounds include palmitoyletha-
nolamide (PEA), oleoylethanolamide (OEA), stearoylethanolamide
(SEA), N-oleoyldopamine (OLDA) and a number of other NAEs
[8].
Despite the abovementioned diversity in central and peripheral
functions, recent studies in animals [9] and humans [10] point to a
major role of EC signaling in both the periphery [10] and central
nervous system [11] in controlling adaptive processes to aversive
situations and regulating and limiting stress reactions. As part of
this protective role under aversive conditions, elevated EC
signaling during stress has been shown to dampen the develop-
ment of anxiety [12] and to regulate the encoding [13], retrieval
[14] and extinction [15] of traumatic memories. Given the fact
that post-traumatic stress disorder (PTSD) is an anxiety disorder
characterized by an inappropriate persistence and uncontrolled
retrieval of traumatic memories, it can be assumed that changes in
EC signaling might play a role in either the development or
persistence of PTSD. This line of reasoning is corroborated by the
observation that patients with PTSD exhibit high rates of cannabis
abuse which may represent a form of self-medication [16], and a
recent study demonstrated that a stimulation of EC signaling in
patients with PTSD by administration of the synthetic cannabi-
noid nabilone resulted in an improvement of memory-related
PTSD symptoms [17].
Although primary fatty acid amides are mainly active in the
brain, there are a number of recent studies which demonstrated
that EC and NAE blood concentrations increase in response to
acute stress [7,10] and that they are higher in individuals who
show stress tolerance [10] and lower in patients with depression
[18]. EC plasma concentrations are also modified by the presence
of affective disorders and severe mental illness [7,8]. Furthermore,
a pilot study by our group in critically ill patients (n = 90) awaiting
cardiac surgery indicated increased plasma concentrations of ANA
and 2-AG in stressed patients with traumatic experiences and
PTSD symptoms as a result of heart disease [19]. The presence of
heart disease, however, could have influenced plasma EC
concentrations [20], and this did not allow the demonstration of
a direct relationship between PTSD symptoms and plasma EC
levels. The current study was therefore performed in a cohort of
physically more healthy subjects who consisted of 1) individuals
with PTSD due to war and torture experiences, 2) trauma-exposed
subjects who did not develop PTSD and 3) healthy controls. The
primary hypothesis we wanted to test was that chronically stressed
individuals with PTSD have increased plasma concentrations of
ECs and NAEs when compared to subjects after trauma exposure
alone who did not develop PTSD and also in comparison to
healthy controls. Our secondary hypothesis was that EC/NAE
plasma levels were positively related to the number of traumatic
events reported by the subjects.
Participants and Procedures
Ethics Statement
All procedures were approved by the Ethical Committees of the
Universities of Konstanz and Munich (protocol# 046-13 and 439-
09) and were carried out in accordance with the Declaration of
Helsinki 2008. Written informed consent was obtained from all
individuals enrolled in the study.
Participants
All trauma-exposed participants were diagnosed at the Center
of Excellence for Psychotraumatology, University of Konstanz,
Germany. We assessed 19 individuals (age: 33.269.8 years, 9
females) with prior trauma exposure (ten of them fulfilled DSM-
IV-TR criteria for current PTSD, whereas 9 had not developed
PTSD) (Table 1). Trauma-exposed participants were refugees
(n = 6 from the Middle East and Afghanistan, n = 6 from Africa,
n = 6 from the Balkan and n= 1 from Eastern Europe), most of
them (84.2%) with a history of persecution, war and torture
experiences. Trauma-exposed participants had multiple traumatic
experiences with 8.866.9 different traumatic event types on the
event checklist of the CAPS [21] as well as 8.162.2 war- and
torture-related events. Average CAPS scores were 94.9615.4 for
the trauma-exposed subjects with PTSD and 24.6624.4 for
trauma-exposed subjects without PTSD (p,0.01, Table 1). PTSD
symptoms in patients with PTSD were present between 6 and 204
months and all patients except one had experienced the traumatic
events during early or late adulthood.
Eight of the trauma-exposed individuals met the DSM-IV
criteria for a current major depressive episode (two subjects from
the trauma exposure only group and six individuals with PTSD,
p= 0.15, Fisher’s exact test) and two subjects from the PTSD
group fulfilled DSM-IV criteria for alcohol dependency. Seven of
the 19 trauma-exposed individuals reported current intake of
anxiolytic, antidepressant, neuroleptic or contraceptive medica-
tion. With the exception of antidepressives, medication use was
equally distributed between traumatized individuals and those
with PTSD (Table 1). Twelve subjects were cigarette smokers.
Four of the trauma-exposed individuals reported chronic somatic
disorders (two had recent treatment for stomach ulcerations, one
had a rheumatic disorder, and one was diagnosed as hepatitis B-
positive). Three of these individuals did not have PTSD and 1
belonged to the PTSD group. None of the study participants took
steroids (neither orally nor by inhalation), had acute illness or
organic disorders such as diabetes, atherosclerotic disease or
obesity (these conditions are known to influence the EC system
[20,22]), had a history of cannabis or other drug abuse or were
abusing drugs at the time of evaluation or had evidence of
psychosis.
Controls were recruited by the Department of Anesthesiology of
the University of Munich (n= 20) and by the Center of
Psychotraumatology of the University of Konstanz (n = 9).
Controls from Munich were of Western European descent and
controls from Konstanz came from the Middle East (n = 6) from
Russia (n = 1), Rumania (n = 1) and Africa (n = 1). Four individuals
from the control group were current cigarette smokers (Table 1).
Procedures
Trauma-exposed individuals as well as those controls who were
recruited by the Centre of Excellence for Psychotraumatology
underwent an extensive standardized clinical interview adminis-
tered by experienced clinical psychologists and trained translators,
starting always at 10:00 h. Upon arrival at the outpatient clinic,
procedures were explained and written informed consent was
obtained. Subsequently, 10 ml of venous blood for EC and cortisol
measurements was drawn around 10:30 h by medical personnel
with the subjects in a comfortable seating position. Afterwards,
sociodemographic as well as medical information was acquired.
Somatic symptoms were assessed using a shortened version of
Screening for Somatoform Symptoms-7 (SOMS-7) [23]. During the
second part of the interview, participants were interviewed in a
standardized manner about the presence of individual traumatic
experiences using the event checklist of the CAPS and the Vivo
Checklist of War, Detention and Torture Events [24] which assesses
common traumatic experiences in conflict regions and during
torture. Subsequently, PTSD symptom frequency and severity
were assessed with the CAPS [21]. The Mini International
Endocannabinoids in Post-Traumatic Stress Disorder
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Neuropsychiatric Interview (MINI) [25] was applied to screen for
potential comorbid mental disorders. In addition, the severity of
depressive symptoms was assessed with the Hamilton Depression
Rating Scale (HAMD) [26].
Control subjects from Munich (n = 20) were interviewed on the
presence or history of acute or chronic physical and mental
disorders, but the abovementioned instruments for the diagnosis of
somatic symptoms, depression, traumatic experiences and PTSD
were not used in these subjects. PTSD was excluded in these
individuals by using the Post-Traumatic Stress Symptom 10
Questionnaire (PTSS-10) [27]. Blood sampling in controls (10 ml)
was performed between 8:00 and 10:00 h.
Endocannabinoid Measurements
We used high-performance liquid chromatography in combi-
nation with tandem mass spectrometry (HPLC-MS-MS) to profile
the plasma of trauma-exposed subjects and healthy controls for the
following ECs and NAEs: ANA, 2-AG, PEA, OEA, SEA, OLDA,
docosatetraenoylethanolamide (DEA), dihomo-c-linolenoyl-etha-
nolamide (DLE) and N-arachidonoyldopamine (NADA). These
compounds were selected because of their presence in human
plasma [8,28,29], their responsiveness to acute stress [7,10,30,31]
or their cannabinomimetic activity [32]. Endocannabinoid mea-
surements, including sample preparation and data interpretation,
were performed at the Department of Anaesthesiology of the
University of Munich in cooperation with the Institute of Doping
Analysis und Sports Biochemistry, Dresden, Germany.
Extraction of the samples. Venous blood samples for EC
measurements were taken and drawn into EDTA-containing tubes
(BD Vacutainer, Franklin Lakes, NY, USA), centrifuged at
3,500 rpm, frozen at –30uC and stored at –80uC until assay.
The time interval between blood sampling and centrifugation was
kept below 10 min because previous experiments have shown that
EC generation in blood samples is continued ex vivo [33,34]. EC
concentrations were determined within a few months after
sampling. EC plasma levels in frozen samples have been shown
to remain stable for at least 6 months [35]. For plasma extraction,
we transferred 500 ml of plasma into a 2 ml reaction tube. Twenty
microliter of internal standard was added consisting of the stable
isotope-labeled ECs and NAEs ANA-d4, 2-AG-d5, PEA-d4,
NADA-d8, SEA-d8, DEA-d4, DLE-d8 and OLDA-d8 (Cayman
Europe, Tallinn, Estonia). The purity of these materials was
.97.2%. Then 1 ml of methyl tertiary-butyl ether (MTBE,
Sigma-Aldrich, Italy) was added and the mixture was vortexed
for 30 s and centrifuged at 12,0006g for 6 min. The clear
supernatant was transferred into a clean 5 ml polypropylene tube
Table 1. Demographic and clinical data of the study groups.
Variable
Trauma-exposed, no PTSD
(n=9)d
Trauma-exposed, PTSD
(n=10)e Controls (n=29)f p
Agea (y) 33.6612.2 33.867.5 33.569.3 0.96
Sex (f/m) 3/6 2/8 17/12 0.08
Educationa (y) 10.164.3 8.763.0* 13.363.1 0.01
Smokers (yes/no) 6/3 6/4 4/25 0.17
Number of cigarettes/day 2.464.0 7.3611.4 1.765.2 0.09
Medication use (yes/no)
Sedatives/anxiolytics 0/9 0/10 0/29 –
Antidepressivesb 2/7 3/7* 0/29 0.01
Mood stabilizers 1/8 1/9 0/29 0.14
Antacids 2/7 2/8 0/29 0.20
Anticontraceptives 2/7 0/10 4/25 0.40
Number of traumatic event typesa
War or torture events 5.265.7 12.066.5* 0.4460.7c ,0.01
CAPS events 7.762.3 8.562.1# 2.761.2c ,0.01
CAPS Scorea 24.6624.4 94.9615.4* 0.0 c ,0.01
CAPS – intrusions 10.669.8 32.865.5* 0.0 ,0.01
CAPS – avoidance 8.466.5 36.268.2* 0.0 ,0.01
CAPS - hyperarousal 8.4.610.0 25.967.6* 0.0 ,0.01
HAMD Scorea 9.9613.5 28.467.8* 2.8066.7c ,0.01
SOMS Scorea 10.2610.0 29.0613.4* 1.864.0c ,0.01
aData are mean6SD; (y) = years; (f) = female; (m) = male.
bTrauma-exposed patients received amitriptylin (n = 2), PTSD patients mirtazapin (n = 2) and amitriptylin+mirtazapin (n = 1).
cThese scores were only available for ethnically matched controls recruited by the Trauma Center of University of Konstanz (n = 9).
dTrauma-exposed individuals without PTSD were of Caucasian origin (n = 6) (two from Iran and two from Turkey, one from Bosnia and one from Afghanistan) and 3 were
Black-Africans (one from Gambia, one from Eritrea and one from Senegal).
eTrauma- exposed individuals with PTSD were Caucasians (n = 8) (two from Turkey, two from Iran, one from Afghanistan, one from Syria, one from Kosovo and one from
Bosnia) and two were Black-Africans (one from Nigeria and one from Togo).
fControls were Caucasians (twenty were Germans, one each were from Turkey, Armenia, Israel, two from Romania and two were Russians) and 2 were from Africa (Eritrea
and Sudan).
*Significantly higher values compared to trauma-exposed individuals without PTSD and to healthy controls.
#Significantly higher values compared to healthy controls.
doi:10.1371/journal.pone.0062741.t001
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(Sarstedt, Numbrecht, Germany) and evaporated under N2 at
37uC. Dried organic phases were then reconstituted in 100 ml of
acetonitrile, vortexed for 30 s, centrifuged at 12,0006g for 6 min
and the clear solution was transferred to HPLC/MS-MS suitable
tubes made of polypropylene.
High performance liquid chromatography-tandem mass
spectrometry. All HPLC-MS-MS analyses were carried out
using an 1100 LC system (binary pump and auto sampler, Agilent,
CA, USA), coupled to an API 4000 mass spectrometer (AB Sciex,
Darmstadt, Germany) equipped with a Turbo-Ion-Spray (ESI)
source. The instrument software Analyst (version 1.5) was used for
data processing. An Agilent Zorbax XDB-C18 analytical column
(3 mm6150 mm, 5 mm particle size) was utilized for chromato-
graphic separation. The mobile phase consisted of (A) 0.1% (v/v)
formic acid (AppliChem, Germany) with 5 mM ammonium
formate (diluted from a 10 M aqueous stock solution, Fluka,
Germany) and (B) methanol (gradient grade) containing 5 mM
ammonium formate buffer and 0.01% (v/v) formic acid. A linear
gradient was employed at a flow rate of 700 l/min from 55% B (at
t = 0–1.2 min) to 100% B (t = 6–9 min), compatible with a source
temperature of 550uC and source gas flow settings (nitrogen as
sprayer and heater gas) of 50 psi. The injection volumes were
50 ml. Selected reaction monitoring (SRM) m/z transitions were:
ANA=348.2/311.3; 2-AG=379.2/269.0; SEA 328.3/311.3;
OEA=326.3/95.1; PEA=300.3/95.1 and OLDA=418.3/
154.2. For calibration, pure solutions of ANA (0.1–2 ng/ml), 2-
AG (1.0–200 ng/ml), OEA (1.0–20 ng/ml), SEA (5–100 ng/ml),
PEA (5–100 ng/ml), OLDA (5–100 ng/ml), DEA (1–5 ng/ml)
and NADA (1–5 ng/ml) (Cayman Europe, Tallinn, Estonia) were
applied. Our method is linear within these calibration ranges. The
lower limit of detection of the method (defined as a signal/noise
ratio .4:1) was 0.025 ng/ml for ANA and 0.33 ng/ml for 2-AG.
In biological matrices, 2-AG (including its deuterated analog) is
rapidly isomerized to 1-AG [29,36]. We therefore quantified 2-AG
as the sum of 2-AG and 1-AG and refer to the sum of both
compounds as 2-AG throughout the paper although this
represents a chemical misnomer.
Cortisol Measurements
Plasma cortisol levels were determined from the same samples
that were used for EC measurements using an automated
immunoassay system based on electrochemiluminescence as the
principle of signal generation (Roche Elecsys, Roche Diagnostics,
Mannheim, Germany). These analyses were performed at the
Institute of Clinical Chemistry of the University of Munich
following the manufacturer’s protocol.
The investigators who performed the measurements were
blinded for the group assignment of the probes.
Statistics
Data are presented as mean6SD, except in the figure where
means6SEM is used to increase clarity. Deviation from normal
distribution of sample data was tested using the Kolmogorov-
Smirnov method. Plasma EC concentrations of healthy controls,
trauma-exposed individuals without PTSD and subjects with
evidence of PTSD were compared using analyses of variance
(ANOVA) in normally distributed data and Kruskal-Wallis
ANOVA on Ranks in case of non-parametric data, followed by
an all pairwise multiple comparison procedure (Holm-Sidak or
Tukey Test, respectively) as post-hoc test to determine which
subgroups were significantly different from each other.
The relationship between continuous variables (e.g. EC levels
and CAPS scores) in normally distributed data was quantified by
calculating Pearson’s r and in case of a non-parametric distribution
with Spearman’s r.
Power analysis for the required sample size based on
effect size estimation. The main hypothesis to be tested in this
study was that plasma EC and NAE concentrations in individuals
with severe traumatic experiences are higher than in nontrauma-
tized controls. We based our sample size estimation on a previous
pilot study in cardiac surgical patients (n = 90) [19] because no
other data on plasma EC concentrations in individuals with
previous traumatic experiences and PTSD symptoms were
available. In this study, patients with multiple traumatic experi-
ences (e.g. from previous myocardial infarction or acute heart
failure) had ANA plasma concentrations of 0.4060.14 ng/ml
[19]. Because baseline ANA plasma levels in healthy individuals
measured with our method is in the range of 0.20 ng/ml, we
assumed a detectable difference of 0.2060.14 ng/ml between
traumatized individuals and healthy controls. Based on an alpha
value of 0.05 and a power of 0.80 and the comparison of 3 groups
(healthy controls, subjects with traumatic experiences but no
PTSD, and patients with PTSD) using ANOVA, we estimated a
sample size of 8 per group to detect significant differences between
groups. To be on the save side (with respect to possible dropouts,
technical problems etc.) we aimed at 20 trauma-exposed
individuals and at least 20 healthy controls.
Results
Demographics and Clinical Data
Trauma-exposed individuals and controls did not differ
significantly with respect to age or gender distribution, but
controls had more years of education. Individuals with PTSD
reported a higher use of antidepressants than non-trauma-exposed
controls. No significant differences were detected with regard to
other types of medication (Table 1). In traumatized individuals,
the number of cigarettes smoked/day correlated with CAPS sum
scores (r = 0.505, p = 0.006). As expected, CAPS, HAMD and
SOMS scores correlated positively with the number of traumatic
event types experienced (CAPS: r=0.70, p,0.01; HAMD:
r=0.71, p,0.01; SOMS: r=0.55, p,0.01).
Endocannabinoid Plasma Concentrations
EC and NAE plasma profiles in trauma-exposed individuals
showed distinct differences between groups. Traumatized subjects
with PTSD showed significantly higher plasma concentrations of
ANA (0.4860.11 vs. 0.3660.14 ng/ml, p = 0.01), 2-AG
(8.9363.20 vs. 6.2662.10 ng/ml, p,0.01), OEA (5.9062.10 vs.
3.8861.85 ng/ml, p,0.01), SEA (2.7063.37 vs. 0.8360.47, ng/
ml, p,0.05) and significantly lower plasma levels of OLDA
(0.1260.05 vs. 0.4560.59 ng/ml, p,0.05) than healthy controls.
Moreover, PTSD patients had higher 2-AG (8.9363.20 vs.
6.0161.32 ng/ml, p = 0.03) and PEA plasma levels (4.0661.87
vs. 2.6361.34 ng/ml, p,0.05) than trauma-exposed individuals
without evidence of PTSD (Figure 1).
Isotope-labeled DEA, DLE and NADA could be readily
detected in the samples but no signals of native DEA, DLE or
NADA could be found in trauma-exposed subjects or controls.
Because depression may influence the EC and NAE systems [7],
and traumatized participants with PTSD had a higher incidence of
major depression than traumatized participants without PTSD, we
compared plasma EC/NAE levels between traumatized individ-
uals diagnosed with depression or using antidepressants with
individuals without these potentially confounding variables in a
secondary analysis. We found no significant effect of depression or
antidepressants on plasma EC/NAE levels (Table 2).
Endocannabinoids in Post-Traumatic Stress Disorder
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Trauma-exposed individuals who reported somatic comorbid-
ities (n = 4) or the use of any type of medication except
antidepressives (n = 5), had nearly identical plasma levels of ECs
or NAEs compared to participants without any comorbidities or
medication use (Table 3). Study participants including healthy
controls who smoked (n = 11) tended to have higher EC/NAE
concentrations than non-smokers (n = 37) but these differences
were not statistically significant (Table 4). We found no statistically
significant correlation between plasma concentration of EC/NAE
compounds and the number of cigarettes smoked/day, neither in
the whole study group (r#0.155, p$0.29, n = 48) nor when only
trauma-exposed individuals with and without PTSD were
included in the analyses (r#0.312, p$0.080, n= 19).
Because it has recently been reported that the EC and NAE
response to stress is different between Caucasians and individuals
with an African genetic background [30], we performed a
secondary analyses excluding non-Caucasian individuals (n = 7)
(one each from Sudan, Namibia, Senegal and Nigeria and two
from Gambia; two of these individuals were from the control
group, 3 were trauma exposed but did not develop PTSD and 2
had PTSD). When non-Caucasians were excluded, differences in
ANA, SEA and OEA in individuals with PTSD in relation to
controls remained significant. OLDA levels remained also
significantly lower but significance was lost after correction for
multiple comparisons. 2-AG and PEA levels were still elevated in
Figure 1. Plasma level comparisons of ECs and related NAEs between non-traumatized control subjects, trauma-exposed subjects
and patients with PTSD. Panel A: ANA plasma concentrations; *significantly higher ANA concentrations in PTSD patients as compared to healthy
controls (diff. of means = 0.120, t = 2.64, *p = 0.012; ANOVA with Holm-Sidak post hoc test). Panel B: 2-AG plasma levels; *significant difference
compared to controls (diff. of means= 2.68, t = 3.12, unadjusted p=0.003, critical level p = 0.017). Panel C: SEA levels: *significant difference compared
to controls (Diff. of means= 1.87, t = 2.77, unadjusted p= 0.008, critical level p = 0.017). Panel D: *significantly higher OEA plasma levels in individuals
with PTSD (diff. of means= 2.01, t = 3.03, unadjusted p=0.004, critical level p = 0.017) compared to controls. Panel E: significant differences in PEA
plasma concentrations compared to individuals after trauma exposure who did not develop PTSD (#p,0.05, diff. of ranks = 16.6, Q = 2.64, Kruskal-
Wallis ANOVA on Ranks with Dunn’s post-hoc test). Panel F: significantly lower OLDA plasma concentrations compared to the control group (*p,0.05,
diff. of ranks = 13.8, Q = 2.45) and in comparison to individuals after trauma exposure without PTSD (#p= 0.05, diff. of ranks = 12.40, Q = 2.75, Kruskal-
Wallis ANOVA on Ranks with Dunn’s post-hoc test). Data are mean 6 SEM.
doi:10.1371/journal.pone.0062741.g001
Table 2. Effect of comorbid depression or the use of
antidepressants on plasma EC/NAE concentrations.
EC/NAE Depression Antidepressives
No (n=10) Yes (n=9) p
No
(n=14) Yes (n =5)p
ANA (ng/ml) 0.4660.08 0.4660.14 0.88 0.4860.09 0.4060.16 0.13
2-AG (ng/ml) 7.1662.30 7.9063.64 0.64 7.9563.10 6.4361.51 0.32
PEA (ng/ml) 3.4062.16 3.4061.41 0.99 3.6061.98 2.8060.73 0.34
OEA (ng/ml) 4.7561.77 5.3062.28 0.58 5.2562.11 4.6761.24 0.45
SEA (ng/ml) 2.6963.60 1.5460.94 0.44 2.5463.01 1.2460.48 0.37
OLDA (ng/ml) 0.2160.13 0.1560.09 0.29 0.1960.12 0.1760.10 0.84
doi:10.1371/journal.pone.0062741.t002
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PTSD patients but the differences to healthy controls were no
longer significant (Figure 2).
Because our control group was ethnically inhomogeneous and
included refugees who did not report exposure to highly traumatic
events nor had evidence of PTSD as well as individuals of German
origin who may have a different health status or differences in the
overall stress exposure, we performed additional analyses and
excluded German subjects from the control group. In this
subanalysis, individuals with PTSD showed still significantly
higher 2-AG concentrations as compared to the ethnically more
comparable controls (n = 9) (8.9363.16 vs. 5.7162.90 ng/ml,
p = 0.02, ANOVA with Holm-Sidak post-hoc test) as well as
significantly lower OLDA concentrations (0.1260.05 vs.
0.1960.08 ng/ml, p= 0.007).
Within the trauma-exposed group (n = 19) the CAPS sum score
and the intrusion subscore correlated positively with PEA plasma
levels (Figure 3). OLDA plasma levels were negatively related to
the CAPS sum score, and all CAPS subscores correlated negatively
with OLDA concentrations (Figure 4). Furthermore, there was a
negative correlation between the number of reported CAPS
traumatic events types and OLDA plasma levels (Figure 5) with no
significant correlations between the other ECs/NAEs measured
and traumatic event types (data not shown).
Cortisol Plasma Concentrations
Cortisol concentrations in trauma-exposed individuals without
PTSD were 14.067.0 mg/dl, 10.267.02 mg/dl in PTSD patients
and 11.266.53 mg/dl in controls, but the difference between
groups was not statistically significant (p = 0.45). There was also no
significant correlation between the number of CAPS traumatic
event types experienced, CAPS, SOMS, and HAMD scores, and
plasma cortisol values. With the exception of a negative
relationship between SAE plasma concentrations and cortisol
levels in traumatized individuals (r =20.55, p = 0.02, n = 19), we
found no correlation between cortisol values and EC/NAE levels.
Discussion
Our findings indicate that individuals with PTSD show
significant differences in plasma concentrations of ECs and NAEs
when compared to healthy controls and to subjects after trauma
exposure who did not develop PTSD. Furthermore, we found
significant correlations between CAPS scores and plasma concen-
trations of the NAEs PEA and OLDA in stressed, trauma-exposed
individuals.
The responsiveness of the EC system in humans to acute stress
has been demonstrated in several recent studies. Stress induced by
the Trier Social Stress Test resulted in a significant increase in
ANA, PEA and OEA plasma concentrations [30]. Physical stress
in trained and physically fit individuals induced by strenuous
exercise during mountaineering or cycling also resulted in elevated
EC concentrations which returned to baseline after termination of
the stressful activity [37,38]. Exposure of healthy volunteers to
kinetic stress during a parabolic flight experiment gave rise to a
significant increase in plasma EC concentrations in stress-tolerant
participants, whereas highly stressed individuals showed an absent
EC response and a massive activation of the hypothalamic-
pituitary-adrenal (HPA) axis [10]. Likewise, patients undergoing
cardiac surgery who showed an impaired EC response during the
stressful postoperative period were at an increased risk for
depression at 6 months after surgery [39]. The latter two findings
may allow speculating that an increased EC signaling during acute
stress is a protective response to maintain homeostasis and
enhance the recovery process. In line with this assumption,
animal experiments showed that the systemic and intracranial
injection of cannabinoids, resulting in an increase in EC signaling,
prevented the effects of intense stress in animal models of PTSD
[40]. The hypothesis that an activation of the EC system increases
stress tolerance in humans needs to be verified in further studies.
Our chronically stressed individuals with PTSD showed
sustained alterations in EC and NAE plasma concentrations
which changed in proportion to PTSD symptom intensity and
were seen long after termination of the actual life-threatening
situation. Comparable observations have been made in the
abovementioned pilot study in patients with severe heart disease
awaiting cardiac surgery where patients with traumatic experi-
ences and a high risk for PTSD showed significantly increased
ANA and 2-AG plasma concentrations [19]. This persistently
activated EC system could suggest the presence of a chronically
increased allostatic load as a result of massive traumatic
experiences. Although a short-term activation of the EC system
during acute stress probably represents an adaptive and protective
response of the organism [11], increased levels of ECs and NAEs
as a result of chronic allostatic load might have both protective and
harmful effects. The possible protective effects of an activated EC
system are illustrated by the fact that patients with major
depression show reduced serum ANA and 2-AG concentrations
[7] and that the use of the CB1 receptor antagonist rimonabant as
an anti-obesity drug has been associated with a significant increase
in the risk for depression. This effect was particularly pronounced
when individuals taking rimonabant faced major stressful events
Table 3. Comorbidities (except depression) or medication
use (except antidepressants) and plasma EC/NAE
concentrations in individuals after trauma exposure.
EC/NAE Comorbidities
a Medication useb
No (n=15) Yes (n=4) p
No
(n=14) Yes (n =5) p
ANA (ng/ml) 0.4760.10 0.4260.15 0.41 0.4660.11 0.4960.10 0.35
2-AG (ng/ml) 7.4462.60 7.9264.12 0.77 7.4262.90 7.8963.00 0.76
PEA (ng/ml) 3.6361.90 3.2061.41 0.29 3.6861.94 2.5760.79 0.24
OEA (ng/ml) 4.9061.63 5.2063.03 0.48 5.1561.94 4.7562.10 0.71
SEA (ng/ml) 2.4862.95 1.9060.84 0.37 2.5963.03 1.9160.30 0.29
OLDA (ng/ml) 0.1860.12 0.2160.10 0.63 0.1860.10 0.1860.11 1.00
aComorbidities were rheumatic disease (n = 1), hepatitis B (n = 1) and chronic
gastritis (n = 2).
bMedications were contraceptives (n = 2), mood stabilizers (n = 1) and antacids
(n = 2).
doi:10.1371/journal.pone.0062741.t003
Table 4. EC/NAE concentrations in smokers vs. non-smokers.
EC/NAE (ng/ml) Cigarette smoking
No (n=37) Yes (n =11) p
ANA (ng/ml) 0.3860.13 0.4760.10 0.12
2-AG (ng/ml) 6.7062.20 7.2263.35 0.57
PEA (ng/ml) 2.9961.27 3.7761.45 0.09
OEA (ng/ml) 4.1262.04 4.9461.51 0.25
SEA (ng/ml) 1.3161.98 0.4160.59 0.45
OLDA (ng/ml) 0.2960.41 0.4160.59 0.51
doi:10.1371/journal.pone.0062741.t004
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[5]. Interestingly, patients with PTSD often abuse cannabinoids
[16] and the use of the synthetic cannabinoid nabilone resulted in
an improvement of symptoms [17]. Thus, despite elevated EC and
NAE plasma concentrations as part of a stress reaction in PTSD
patients, the enhanced endocannabinoid signaling might be
insufficient to completely restore homeostasis and a further
reduction in symptoms by exogenous cannabinoids is possible. A
likely explanation for this phenomenon is that the chronic
elevation of EC and NAE levels in traumatized individuals could
result in a desensibilisation or downregulation of one or more
receptor types for ECs or NAEs. This possibility has been
described in individuals with intolerance to acute stress and an
inadequate EC response during a parabolic flight experiment [10].
Although an enhanced EC signaling may have protective and
adaptive effects during or after a major stress exposure, there is
evidence of elevated plasma levels of ANA and 2-AG in patients
with atherosclerosis and coronary artery disease [20,41], whereas
an inhibition of EC signaling by CB1 receptor blockade in
circulating macrophages is associated with a significant reduction
in pro-inflammatory mediators [20]. Activated macrophages and
other nuclear blood cells are believed to be the major source of
circulating ECs in blood [33,42]. Therefore, an activated
peripheral EC system might play a causal role in the reported
increased risk for coronary artery disease and the associated
enhanced mortality in patients with PTSD [43]. This assumption
is corroborated by the observation that the number of cigarettes/
day smoked by traumatized individuals in our study correlated
with CAPS summary scores and that smokers tended to exhibit
higher EC/NAE plasma concentrations, albeit without a direct
correlation between EC/NAE concentration and the amount of
daily tobacco consumption. One could therefore argue that the
increased activity of the EC system in traumatized individuals
observed in our study could help to maintain homeostasis in the
short term but might have long-term adverse consequences. These
assumptions need, however, experimental and clinical confirma-
tion.
The interpretation of our findings is seriously hampered by the
fact that little detailed knowledge exists regarding the multiple
biological effects of many of the only very recently discovered ECs
and NAEs measured in our study. Furthermore, the mechanisms
leading to changes in peripheral EC and NAE concentrations are
at present only incompletely understood and the important
question whether changes in EC and NAE signaling reflect
Figure 2. Subanalysis of plasma concentrations of ECs and related NAEs after excluding individuals of African descent (n=7). Panel
A: significantly higher ANA plasma concentrations in PTSD patients as compared to healthy controls (diff. of means= 0.136, t = 2.64, *p = 0.035;
ANOVA with Holm-Sidak post hoc test). Panel C: significantly higher SEA plasma levels compared to controls (diff. of ranks = 12.9, Q = 2.96, p,0.05;
Kruskal-Wallis ANOVA on Ranks with Dunn`s post hoc test). Panel D: significantly increased OEA concentrations in PTSD patients in relation to healthy
controls (diff. of ranks = 11.9, Q = 2.47, p,0.05; Kruskal-Wallis ANOVA on Ranks with Dunn`s post hoc test). Panel F: OLDA concentrations across the 3
study subgroups (Kruskal-Wallis ANOVA on Ranks indicated a significant difference among the groups (+p= 0.02) but significance was lost after
correction for multiple comparisons (diff. of ranks 11.7, Q = 2.23, p.0.05). The differences between groups shown in Panel B (2-AG) and Panel E (PEA)
were not statistically significant in the subanalysis. Data are mean 6 SEM.
doi:10.1371/journal.pone.0062741.g002
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pathological or protective responses of the organism after trauma
exposure is difficult to address.
Other limitations of our study result from the fact that we
measured peripheral plasma concentrations of ECs/NAEs where-
as most effects of lipid signaling molecules on stress and memory
are central [13–15,44]. There is, however, evidence that ECs and
related compounds are able to cross the blood-brain barrier [45].
Furthermore, recent animal experiments have demonstrated the
possibility of a parallel activation of the peripheral and central EC
system during stressful conditions. The stress of footshock delivery
to rats resulted in an almost simultaneous increase in ANA
concentrations in blood and several memory–related brain areas
including the amygdala and hippocampus (Hauer D., Campo-
longo P. et al., in preparation). The systemic administration of
OEA to rats, resulting in elevated OEA plasma levels as seen in
our PTSD patients, improved memory of aversive training
experiences [46]. These findings suggest that changes in peripheral
EC/NAE concentrations may indeed reflect alterations in central
EC signaling along with EC/NAE associated behavioral effects.
One should keep in mind, however, that animal studies have also
shown that stress reduces brain EC concentrations [44]. Thus, the
source and regulation of circulating ECs/NAEs during stress needs
to be addressed in further studies.
Additional limitations of our study result from ethnical
differences within the subject pool we investigated. The individuals
we studied had different racial backgrounds and included
Caucasians and Africans. A recent study has shown that the lipid
response to acute stress is significantly higher in Caucasians than in
African-Americans [30]. Although these findings cannot necessary
be extrapolated to chronic trauma-induced stress conditions, we
performed an additional exploratory subanalysis excluding indi-
viduals of African origin. Despite the loss of statistical power by
this approach, higher plasma EC concentrations in PTSD patients
could be confirmed in this more homogenous sample and the
group differences in ANA, SEA and OEA remained significant
whereas OLDA concentrations still showed a strong trend towards
lower values. In order to control for our inhomogeneous control
group which included individuals of German origin as well as
immigrants with refugee status in Germany, we further compared
EC/NAE plasma concentrations among subgroups with German
subjects excluded from controls. In this more uniform sample,
individuals with PTSD still showed significantly higher plasma
concentrations of 2-AG and significantly lower levels of OLDA.
Beside the lower statistical power due to the smaller control group,
the loss of significance in ANA, SEA and OEA was due to
increased EC/NAE levels in the remaining controls. These
individuals did not report exposure to highly traumatic events
Figure 3. Correlation between CAPS scores and PEA plasma levels in individuals after trauma exposure (n=19). Panel A: CAPS sum
score (r = 0.54, p = 0.02); Panel B: CAPS – intrusion subscore (r = 0.65, p,0.01); Panel C: CAPS – avoidance subscore (r = 0.21, p = 0.40); Panel D: CAPS -
hyperarousal subscore (r = 0.29, p = 0.23). Solid line indicates regression line and dotted lines 95% confidence intervals.*marks significant correlations.
doi:10.1371/journal.pone.0062741.g003
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nor had evidence of PTSD but were still refugees who found
shelter in Germany. They were almost certainly exposed to higher
stress levels during immigration which could result in increased
plasma lipid signaling, although this possibility is difficult to proof
with the questionnaires and instruments used in our study. Thus,
when compared to our original control group, individuals with
PTSD showed significantly higher plasma concentrations of ANA,
2-AG, SEA and OEA and significantly lower levels of OLDA.
When individuals of African origin were excluded, ANA, SEA and
OEA remained significantly elevated; 2-AG and PEA levels were
still higher and OLDA concentrations still lower but statistical
significance was lost with regard to the latter three compounds.
When only refugees with presumed differences in stress exposure
were compared, only 2-AG levels remained significantly higher
and OLDA concentrations significantly lower. This suggests that
these two compounds may represent more robust indicators of the
presence of PTSD but these assumptions definitively need to be
corroborated in larger studies.
It is of interest to note that plasma concentrations of ECs and
NAEs in trauma-exposed individuals who did not develop PTSD
were often between those of controls and those of subjects with the
full syndrome of PTSD. This suggests stress-dose dependent
changes in lipid signaling which is also corroborated by our
observation that CAPS and CAPS subscores correlated with EC/
NAE plasma levels.
Figure 4. Relationship between OLDA plasma concentrations and CAPS scores. Panel A: CAPS sum score (r =20.68, p,0.01, n = 19); Panel
B: CAPS – intrusion subscore (r =20.65, p,0.01); Panel C: CAPS – avoidance subscore (r =20.59, p,0.01); Panel D: CAPS – hyperarousal subscore
(r =20.66, p,0.01). Solid line indicates regression line and dotted lines 95% confidence intervals.
doi:10.1371/journal.pone.0062741.g004
Figure 5. Correlation between the number of CAPS traumatic
event types and OLDA plasma concentrations (r =20.50,
p=0.03, n=19). The solid line represents the regression line and
dotted lines 95% confidence intervals.
doi:10.1371/journal.pone.0062741.g005
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Individuals who developed PTSD had experienced a signifi-
cantly higher number of war and torture events than traumatized
subjects without PTSD and this raises the possibility that the
greater intensity of the original stress exposure, rather than PTSD
itself, may be the actual cause of the observed differences in our
study. However, we found no significant relationship between the
number of traumatic event types reported by our study subjects
and EC/NAE plasma concentrations, which correlated only with
PTSD symptom severity.
Study participants with PTSD had a higher incidence of
depression and also reported a higher use of antidepressants. The
association between PTSD and depression is, however, complex.
Depression is known to be associated with lower EC plasma levels
[7,39] whereas our individuals with PTSD showed increased
concentrations. Moreover, our secondary analyses showed no
differences in EC/NAE plasma concentrations in traumatized
individuals on antidepressants and between depressed and non-
depressed individuals. Thus, if depression and the use of
antidepressants have an effect on our finding of increased EC/
NAE plasma levels in PTSD patients one could assume that these
confounders may have actually resulted in lower rather than
increased plasma concentrations. Nevertheless, the role of
depression in EC signaling in the presence of PTSD definitively
needs further studying in larger cohorts.
PTSD patients may show higher stress responsiveness than
healthy controls and could thus react more to the stress of blood
sampling, which could result in higher EC/NAE plasma levels.
These effects are difficult to control for, but all our subjects
appeared to be comfortable during blood drawing and were
habituated to the procedure from previous medical visits.
Despite these limitations, our findings indicate that PTSD is
associated with changes in the pattern of plasma EC/NAE
concentrations. This finding may have both pathophysiological as
well as diagnostic consequences for PTSD but needs to be
reproduced in larger and more homogenous study groups.
Likewise, early (e.g. during childhood) trauma exposure may have
very different effects on the EC system than later in life and this
possibility should also addressed in further studies.
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